I think it's important to emphasise that whilst TLX, with a market cap of $5+ billion, has already got an established and highly profitable business in the very same radiopharmaceutical treatment of patients with prostate cancer.
This new "upstart" Clarity, with a market cap now approaching A$1 billion, has become a very serious threat to Telix through what appears to be a best-in-class imaging and therapy via its Cu64/Cu67 radioligand.
And Clarity's platform clearly has the potential to extend way beyond prostate cancer over time.
I'd certainly be worried if I was the CEO of TLX.
Ann: Clarity strengthens Cu-64 network with new supply agreement, page-17
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.98 |
Change
-0.220(4.23%) |
Mkt cap ! $1.551B | |||
| Open | High | Low | Value | Volume |
| $5.10 | $5.20 | $4.92 | $4.336M | 862.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 11336 | $4.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.98 | 207 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |